Advertisement
BDX or COO or TMO
Which Stock Would AI Choose? Becton, Dickinson and Company (BDX) vs. The Cooper Companies (COO) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- BDX, COO, and TMO operate in the healthcare sector with exposure to medical devices and life sciences, offering investors diversified ways to participate in industry trends.
- TMO delivered stronger recent momentum following its Q2 2026 earnings beat, with revenue growth of approximately 10% year-over-year.
- COO maintains a narrower focus on vision care and surgical products, with its stock trading near $72 as of late July 2026 amid steady sector conditions.
- BDX provides broad medical technology solutions, showing relatively stable performance in recent market activity compared to peers with earnings catalysts.
- Valuation sensitivity varies, with TMO benefiting from life sciences demand recovery while BDX and COO emphasize operational consistency in their segments.
- Market sentiment reflects sector-wide factors such as healthcare spending and innovation pipelines, with relative performance tied to individual earnings delivery and guidance.
Introduction
Investors and traders seeking exposure to the healthcare sector often evaluate medical technology and life sciences companies for their defensive growth characteristics and innovation-driven returns. BDX, COO, and TMO represent distinct yet overlapping segments within this space, allowing for meaningful comparisons of business models, recent price behavior, and positioning amid evolving market conditions. This analysis appeals to those assessing relative performance across established players with global operations and varying degrees of cyclical sensitivity to healthcare budgets and technological adoption.
BDX Overview and Recent Performance
Becton, Dickinson and Company develops and manufactures medical devices, diagnostics, and laboratory equipment serving hospitals, laboratories, and pharmaceutical companies worldwide. In recent weeks, the stock has exhibited measured stability, influenced by steady demand for core products such as syringes, catheters, and infusion systems. Broader market activity in the medical technology space, including supply chain normalization and ongoing innovation in patient safety solutions, has supported sentiment without sharp volatility. Performance has aligned closely with sector peers, reflecting consistent operational execution rather than outsized catalysts in the immediate period.
COO Overview and Recent Performance
The Cooper Companies, Inc. focuses on contact lenses through its CooperVision segment and women's health and surgical products via CooperSurgical. Recent market activity has shown the shares trading in a narrow range around $72 as of late July 2026, supported by steady consumer and professional demand for vision correction products. Developments in the eyecare market, including expanding myopia management offerings, have contributed to a neutral-to-positive tone. Relative performance has remained consistent with broader healthcare trends, with limited swings tied to macroeconomic factors affecting discretionary medical spending.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. provides scientific instruments, reagents, and services for research, diagnostics, and biopharma applications. The company reported robust Q2 2026 results with revenue reaching $11.99 billion, reflecting approximately 10% year-over-year growth and surpassing analyst expectations. This performance, driven by accelerating organic demand across life sciences and laboratory products, lifted sentiment in recent weeks. The stock experienced positive momentum post-earnings before some consolidation, highlighting its sensitivity to broader biotech and research funding trends within the sector.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots optimized for prevailing market conditions. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, yet only those demonstrating the strongest alignment with current trends, risk parameters, and performance metrics earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, and statistical profiles, with historical win rates and returns varying across configurations. Readers interested in exploring automated approaches to stocks like these can review the full range of options directly on the platform.
Head-to-Head Comparison
Business models differ notably: BDX emphasizes a wide array of hospital and laboratory consumables with recurring revenue elements, COO concentrates on vision and fertility-related devices with consumer and professional channels, and TMO centers on high-margin instrumentation and services tied to research and development cycles. Growth drivers reflect these focuses, with TMO showing recent acceleration from life sciences recovery while BDX and COO rely more on steady replacement demand. Recent momentum favors TMO following its earnings beat, contrasting with the steadier trajectories of the other two. Risk factors include regulatory and reimbursement pressures common to healthcare, alongside varying exposure to global supply chains and innovation pipelines. Valuation sensitivity appears higher for growth-oriented names like TMO, while market sentiment across all three remains anchored to sector fundamentals rather than isolated events.
Tickeron AI Verdict
Based on observable factors including trend consistency following earnings delivery and relative positioning within the healthcare sector, Tickeron’s AI would currently assign a higher probabilistic preference to TMO. Its recent revenue growth and guidance updates provide clearer short-term catalysts compared to the more stable but less dynamic profiles of BDX and COO. This assessment remains probabilistic and subject to ongoing market developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BDX’s FA Score shows that 2 FA rating(s) are green whileCOO’s FA Score has 1 green FA rating(s), and TMO’s FA Score reflects 3 green FA rating(s).
- BDX’s FA Score: 2 green, 3 red.
- COO’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BDX’s TA Score shows that 4 TA indicator(s) are bullish while COO’s TA Score has 4 bullish TA indicator(s), and TMO’s TA Score reflects 3 bullish TA indicator(s).
- BDX’s TA Score: 4 bullish, 4 bearish.
- COO’s TA Score: 4 bullish, 4 bearish.
- TMO’s TA Score: 3 bullish, 4 bearish.
Price Growth
BDX (@Pharmaceuticals: Other) experienced а +6.79% price change this week, while COO (@Pharmaceuticals: Other) price change was +2.64% , and TMO (@Medical Specialties) price fluctuated +3.43% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.34%. For the same industry, the average monthly price growth was +5.49%, and the average quarterly price growth was +2.67%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +7.00%. For the same industry, the average monthly price growth was +8.22%, and the average quarterly price growth was +20.26%.
Reported Earning Dates
BDX is expected to report earnings on Nov 05, 2026.
COO is expected to report earnings on Sep 09, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (+4.34% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (+7.00% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BDX | COO | TMO | |
| Capitalization | 48.2B | 14.5B | 220B |
| EBITDA | 4.97B | 890M | 12B |
| Gain YTD | 17.448 | -9.431 | 0.298 |
| P/E Ratio | 30.60 | 62.91 | 31.97 |
| Revenue | 22.2B | 4.23B | 46.3B |
| Total Cash | N/A | 139M | 4.06B |
| Total Debt | 17.3B | 2.46B | 42.5B |
BDX | COO | TMO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 34 | 13 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 65 Fair valued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 95 | 100 | 80 | |
SMR RATING 1..100 | 87 | 89 | 61 | |
PRICE GROWTH RATING 1..100 | 15 | 49 | 14 | |
P/E GROWTH RATING 1..100 | 67 | 11 | 31 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (8) in the Medical Specialties industry is in the same range as TMO (12) and is somewhat better than the same rating for COO (65). This means that BDX's stock grew similarly to TMO’s and somewhat faster than COO’s over the last 12 months.
TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as BDX (95) and is in the same range as COO (100). This means that TMO's stock grew similarly to BDX’s and similarly to COO’s over the last 12 months.
TMO's SMR Rating (61) in the Medical Specialties industry is in the same range as BDX (87) and is in the same range as COO (89). This means that TMO's stock grew similarly to BDX’s and similarly to COO’s over the last 12 months.
TMO's Price Growth Rating (14) in the Medical Specialties industry is in the same range as BDX (15) and is somewhat better than the same rating for COO (49). This means that TMO's stock grew similarly to BDX’s and somewhat faster than COO’s over the last 12 months.
COO's P/E Growth Rating (11) in the Medical Specialties industry is in the same range as TMO (31) and is somewhat better than the same rating for BDX (67). This means that COO's stock grew similarly to TMO’s and somewhat faster than BDX’s over the last 12 months.
| BDX | COO | TMO | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 70% | 4 days ago 73% | 2 days ago 62% |
| Stochastic ODDS (%) | 2 days ago 57% | 2 days ago 56% | 2 days ago 61% |
| Momentum ODDS (%) | 2 days ago 48% | 2 days ago 59% | N/A |
| MACD ODDS (%) | 2 days ago 47% | 2 days ago 71% | 2 days ago 63% |
| TrendWeek ODDS (%) | 2 days ago 47% | 2 days ago 54% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 50% | 2 days ago 50% | 2 days ago 61% |
| Advances ODDS (%) | 6 days ago 44% | 4 days ago 56% | 2 days ago 61% |
| Declines ODDS (%) | 17 days ago 43% | 9 days ago 60% | 5 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 51% | 2 days ago 58% | 2 days ago 56% |
| Aroon ODDS (%) | 2 days ago 51% | 2 days ago 57% | 2 days ago 57% |
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | -0.12% | ||
| COO - BDX | 54% Loosely correlated | +1.24% | ||
| BAX - BDX | 52% Loosely correlated | +2.00% | ||
| TMO - BDX | 50% Loosely correlated | +2.41% | ||
| CNMD - BDX | 48% Loosely correlated | -1.31% | ||
| MMSI - BDX | 45% Loosely correlated | +1.54% | ||
More | ||||
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with BDX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then BDX could also see price increases.